• Bristol-Myers Squibb Q2 2026 total revenues rose 5.7% to USD 13 billion; GAAP diluted EPS climbed to USD 1.62 from USD 0.64.
• Non-GAAP diluted EPS increased 39.7% to USD 2.04; gross margin slipped 1.2 percentage points to 71.3%.
• Growth Portfolio revenue rose 15% to USD 7.6 billion; Opdivo net sales fell 3% to USD 2.49 billion.
• Eliquis net sales rose 22% to USD 4.48 billion; Camzyos more than doubled to USD 416 million.
• Raised 2026 non-GAAP revenue outlook to about USD 49-50 billion; lifted non-GAAP EPS view to USD 6.75-7.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bristol-Myers Squibb Company published the original content used to generate this news brief on July 30, 2026, and is solely responsible for the information contained therein.